-

05:36:43 PM

OKYO Stock News

OKYO - OKYO Pharma Limited

03/16/23 3:01 AM

Nasdaq : OKYO

clinical triallow float

OKYO Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry Eye Disease is now listed on the ClinicalTrials.gov Public Website

OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today

RHEA-AI

neutral

03/14/23 3:00 AM

Nasdaq : OKYO

low float

OKYO Pharma Limited announces U.S.$5.74 million Global Private Placement and investment by directors and members of senior management

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS

RHEA-AI

neutral

03/13/23 4:15 PM

Nasdaq : OKYO

low float

OKYO Pharma Limited Prices $5.3 Million Offering of ADSs

OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) (“OKYO Pharma” or the “Company“), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases (“DED”) and ocular pain, announced the pricing of a

RHEA-AI

neutral

02/28/23 2:00 AM

Nasdaq : OKYO

clinical triallow float

OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease

OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today

RHEA-AI

neutral

02/23/23 2:00 AM

Nasdaq : OKYO

managementlow float

OKYO Pharma Announces Appointment of Dr. Jay S. Pepose to Its Scientific Advisory Board

OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical

RHEA-AI

neutral

02/21/23 7:00 AM

Nasdaq : OKYO

conferenceslow float

OKYO Pharma to Present at the Second Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA on February 21-23, 2023.

OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) (“OKYO”, “OKYO Pharma” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in this

RHEA-AI

neutral

12/30/22 2:00 AM

Nasdaq : OKYO

low float

OKYO Pharma Limited - Interim Results for the Six Months Ending 30 September 2022

OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat Dry Eye Disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announces its

RHEA-AI

neutral

12/22/22 2:00 AM

Nasdaq : OKYO

low float

OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease

RHEA-AI

neutral

12/21/22 2:00 AM

Nasdaq : OKYO

conferenceslow float

OKYO to Participate at Biotech Showcase

OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in the multi-billion-dollar dry eye disease market,

RHEA-AI

neutral

12/06/22 2:00 AM

Nasdaq : OKYO

low float

OKYO Pharma Limited ("OKYO" or the "Company") - OKYO publicly files a registration statement with the SEC

OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in the multi-billion-dollar market, announces, that

RHEA-AI

neutral